Notícias e Atividades da Vertex Pharmaceuticals
Presença
Vertex Pharmaceuticals é uma das ...
- Forbes Global 2000 (#553);
- Fortune 500 (#400);
- Global Fortune 500 (#385);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Vertex Pharmaceuticals é uma empresa listada sob o símbolo VRTX (US).
Vertex Pharmaceuticals tem presença direta em 2 países.
Eles estão dentro:
- Biotecnologia67%
- Farmacêutica33%
Fusão, aquisição e financiamento envolvendo Vertex Pharmaceuticals.
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado em 16 de abril de 2024).
Executivos
Veja o organograma con seus 65 executivos principais
Biografias mais buscadas da Vertex Pharmaceuticals
- Reshma Kewalramani, Director, President and Chief Executive Officer
- Jeffrey Leiden, Executive Chairman of the Board
- Sangeeta Bhatia, Director
Recentes movimentos de executivos em Vertex Pharmaceuticals
- William Mckernan, ingressou na Companhia como Financial Planning and Analysis Manager (Notícia publicada em 29 de maio de 2025).
- David Jimenez, ingressou na Companhia como Senior Vice President, New Product, North America (Notícia publicada em 14 de maio de 2025).
Criar um alerta
para seguir os movimentos de executivos da Vertex Pharmaceuticals.
Biotecnologia
Vertex Pharmaceuticals possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).
Popular M&A news in Biotecnologia
- Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
- BioNTech has announced the acquisition of CureVac (publicado em 12 de junho de 2025).
- SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Vertex Pharmaceuticals
- Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY | Vertex Pharmaceuticals Newsroom
- Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | Vertex Pharmaceuticals Newsroom
- Vertex to Participate in Upcoming Investor Conferences | Vertex Pharmaceuticals Newsroom
- Vertex Reports First Quarter 2025 Financial Results | Vertex Pharmaceuticals Newsroom
- Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis | Vertex Pharmaceuticals Newsroom
- European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis | Vertex Pharmaceuticals Newsroom
- Vertex to Announce First Quarter 2025 Financial Results on May 5th | Vertex Pharmaceuticals Newsroom
- Vertex Announces Program Updates for Type 1 Diabetes Portfolio | Vertex Pharmaceuticals Newsroom
- Videos | Vertex Pharmaceuticals Newsroom
- Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis | Vertex Pharmaceuticals Newsroom
- View more press releases Close
Redes sociais sobre Vertex Pharmaceuticals
- Vertex Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Vertex Pharmaceuticals na LinkedIn, Twitter e YouTube
